Purdue University researchers developed a targeted microRNA therapy, using a modified version of microRNA-34a, which slows cancer cell division by suppressing genes like MET, CD44, and AXL. This therapy demonstrated stability in mouse models, showing tumor growth control and gene suppression for over 120 hours without triggering the immune system. Attached to a folate molecule for precision delivery, it leverages cancer cells’ folate receptors for targeted effects, with promising potential as a standalone or combination therapy for drug-resistant cancers.

For details, visit Purdue’s news page.